According to another large-scale clinical study, incretin-based therapy by GLP-1 agonists or DPP-4 inhibitors showed a trend for decreased risk of hospitalization for heart failure (1,499,650 patients, with 29,741 hospitalized for heart failure) [ 225 ].
← all excerpts
Vascular Inflammation and Oxidative Stress: Major Triggers for Cardiovascular Disease.
1
—
—